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Abstract
Background: Type 2 diabetes is associated with increased levels of Angiopoietin-2 (Ang-2) and soluble Tie-2 (sTie-
2), but its impact on vascular disease is still unknown. This study aimed to further explore the associations of Ang-2
and sTie-2 with metabolic control and diabetic complications.
Methods: In a cross-sectional designed study, levels of Ang-2 and sTie-2 as well as their relationships to
cardiometabolic parameters were determined in 80 type 2 diabetic subjects (age 65 ± 7 years, female 47.4%).
Results: After controlling for age and BMI, Ang-2 levels were associated with levels of sTie-2, diastolic blood
pressure, plasma insulin, homeostasis model assessment of insulin resistance (HOMA-IR), creatinine, glomerular
filtration rate (GFR), and gamma-glutamyl transferase (GGT) (all p < 0.02). Presence of diabetic macrovascular
complications, polyneuropathy and insulin therapy were associated with higher Ang-2 levels (p < 0.05). Conversely,
sTie-2 levels were associated with glycated hemoglobin (HbA1c), fasting plasma glucose and insulin, HOMA-IR,
triglyceride, and liver function parameters (all p < 0.03). Multiple linear regression analysis showed that Ang-2
remained significantly associated only with levels of GGT (p < 0.04), whereas sTie-2 remained significantly
associated with HbA1c, insulin levels, and HOMA-IR (p < 0.03). No differences in Ang-2 and sTie-2 levels were
observed with regard to gender of participants.
Conclusions: Ang-2 is independently associated with levels of GGT while sTie-2 is independently associated with
levels of HbA1c, plasma insulin and HOMA-IR in type 2 diabetic subjects. Therefore we suggest that the associations
of Ang-2 and sTie-2 with type 2 diabetes are based on different patho-physiological mechanisms.
Background
Angiopoietins are growth factors that promote angiogen-
esis together with vascular endothelial growth factor
(VEGF). Among the four identified angiopoietins (1-4),
Angiopoietin (Ang)-1 and Ang-2 are reported to be
required for the formation of mature blood vessels, as
demonstrated by mouse knock out studies [1,2]. Ang-2 is
expressed primarily in the vascular endothelium at sites of
vascular remodeling [3]. Both Ang-1 and Ang-2 act by
binding to the endothelium-specific receptor tyrosine
kinase 2 (Tie-2). A soluble form of the Tie-2 receptor can
be detected in human biological fluids [4]. The Ang/Tie
system tightly controls the endothelial phenotype during
angiogenesis and vascular inflammation in a unique fash-
ion. While Ang-1 has an agonistic effect on Tie-2 through
induction of autophosphorylation of the receptor neces-
sary for the stabilization of the blood vessels [5], Ang-2
appears to have an antagonistic effect. It acts as a competi-
tive inhibitor of Ang-1 for Tie-2 binding, thereby inhibit-
ing Ang-1/Tie-2 signaling [6]. Consequently, the loss of
Tie-2 signaling destabilizes the endothelium and facilitates
the angiogenic and inflammatory response to growth
factors and cytokines [7]. Ang-2 promotes also VEGF
induced neovascularization.
Growing evidence suggests an involvement of Ang-2
and its receptor Tie-2 in the pathophysiology of differ-
ent vascular and inflammatory diseases such as arterio-
sclerosis [8], hypertension [9], idiopathic pulmonary
arterial hypertension [10], chronic kidney disease [11],
and rheumatoid arthritis [12].
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any medium, provided the original work is properly cited.Type 2 diabetes mellitus is a metabolic disease character-
ized by chronic hyperglycemia which mainly results from a
deficiency in peripheral insulin effects (insulin resistance).
However, the morbidity and mortality of diabetes are
mainly attributed to the development of both macrovascu-
lar and microvascular complications. Among factors such
as obesity, hypercholesterolemia, hyperlipidemia, increased
formation of advanced glycation end-products [13] and
increased oxidative stress [14], a dysfunction in angiogen-
esis also has been suggested as a common origin for dia-
betic vascular complications [15]. In addition, previous
studies reported an elevation of plasma levels of VEGF,
Ang-2 and soluble Tie-2 (sTie-2) in subjects with type 2
diabetes mellitus [16,17]. A selective increase of plasma
levels of Ang-2 and sTie-2, but not Ang-1, is accompanied
by neovascularization and endothelial abnormalities.
Endothelial abnormalities are closely linked to the patho-
physiology of microvascular and atherosclerotic vascular
complications in type 2 diabetes [18,19]. Although a pre-
vious study showed that raised levels of plasma Ang-2 and
VEGF in diabetes are independent of concomitant vascular
disease [20], the underlying mechanisms for the association
of Ang-2 and sTie-2 with type 2 diabetes are not well
u n d e r s t o o d .U pt on o w ,t h e r ea r en op u b l i s h e dd a t ao n
plasma levels of both Ang-2 and sTie-2 in subjects with
type 2 diabetes mellitus evaluating their relationships with
metabolic and glycaemic parameters, liver and renal func-
t i o n ,a n dl i p i dp r o f i l e .T h e r e f o r e ,i nt h i sc r o s s - s e c t i o n a l
study, we aimed to further explore the relationship
between circulating Ang-2 and sTie-2 levels in type 2 dia-
betic subjects and to identify factors that might influence
or predict their levels.
Methods
T h es t u d yw a sa p p r o v e db yt h eM e d i c a lU n i v e r s i t yo f
Vienna Ethics Committee and included 80 type 2 diabetic
subjects (age 65 ± 7 years, time since diagnosis of diabetes
15 ± 9 years, BMI 32 ± 6, shown as mean ± standard
deviation). All participants were recruited at the Outpati-
ent Clinic of Diabetes, Division of Endocrinology and
Metabolism, Department of Internal Medicine III. Written
informed consent was provided by all participants prior to
the study. The participants fulfilled the following inclusion
criteria: established type 2 diabetes mellitus (diagnosed
according to WHO criteria [21]), age 40-80 years, under
oral anti-diabetic and/or insulin therapy, intact hepatic
function as evaluated by aspartate aminotransferase (AST)
or alanin aminotransferase (ALT) not more than 2 times
the upper reference limit and intact renal function as eval-
uated by glomerular filtration rate > 50 mL/min/1.73 m
2,
no history of recent (< 6 months) cardiac, cerebral or
peripheral infarction, no history of Charcot’sd i s e a s eo r
chemotherapy, and no glucocorticoid or other hormone
substitution therapy. Presence of diabetic polyneuropathy
was established by evaluation of nerve conduction velocity
for upper and lower extremities. Presence of overt macro-
vascular complications was established by a history of pre-
vious (> 6 months) stroke, myocardial infarction, angina,
and coronary or peripheral revascularization.
Prior to blood sampling, a disease-specific questionnaire
concerning duration since diagnosis of diabetes, type of
anti-diabetic therapy, incidence of diabetic complications,
presence of any other chronic disease and cigarette and
alcohol consumption of the patients was filled out with
the participants. Blood pressure, height, and waist circum-
ference of all participants were measured and body mass
index (BMI) was determined. Fasting venous blood sam-
ples were obtained from a cubital vein. One sample was
allowed to clot for approximately one hour on ice and was
then centrifuged at 3000 rpm for 10 minutes. Plasma was
separated and stored in aliquots at -28°C until Ang-2 and
sTie-2 were analyzed. In a routine biochemistry laboratory,
glycated hemoglobin (HbA1c) was determined (Haemoglo-
bin Testing System, D-10, Bio-Rad Laboratories, Inc) and
levels of fasting plasma glucose (using the hexokinase
method), C-peptide, insulin, lipid profile, liver and renal
function parameters were measured in the central clinical
laboratory of the General Hospital of Vienna, Vienna,
Austria using commercially available assays. Furthermore,
urine samples were obtained from all participants and
were tested for the presence of glucose, protein and albu-
min. In addition, HOMA-IR was calculated by multiplying
the value of fasting plasma glucose (mg/dl) by the value of
fasting plasma insulin (μU/ml) divided by 405. Waist to
height ratio was calculated by dividing the waist circum-
ference by the height (both in cm) of participants. Glomer-
ular filtration rate was estimated using MDRD Study
Equation [22]. Circulating levels of plasma Ang-2 and
sTie-2 were assayed using commercially available Quanti-
kine human ELISA kits (R&D systems, Abingdon, UK).
The intra-and inter-assay coefficients of variation were
6.5% and 9.1%, respectively, for Ang-2 and 4.4% and 6.5%,
respectively, for Tie-2. The assays were performed accord-
ing to the manufacturer’si n s t r u c t i o n s .
Statistical analysis
Collected data were subjected to the Kolmogorov-Smirnov
test to determine their distribution. Not normally distribu-
ted data were log (base 10)- transformed for all following
analyses and presented as median and range. Statistical
comparisons of the obtained data were performed using
independent samples t-tests. Pearson’s correlations test
was used to determine the associations of Ang-2 and
Tie-2 with age and BMI. Partial (two-tailed) correlation
tests adjusted for age and BMI were used to study the
associations of Ang-2 and Tie-2 to other measured vari-
ables. Linear multiple regression analysis was used to
determine independent predictors for Ang-2 and sTie-2.
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w i t hA n g - 2o rs T i e - 2i nt h ep a r t i a lc o r r e l a t i o nt e s tw e r e
included in the analysis as independent variables. For all
statistical tests, a value of p < 0, 05 was considered to be
significant. Data entry and analysis were performed using
SPSS version 17.0 (Chicago, Illinois).
Results
1. Clinical characteristics of type 2 diabetic participants
and circulating levels of Ang-2 and sTie-2
Eighty diabetic subjects (47.7% female) were studied.
Among them, 50% presented with diabetic polyneuropathy
(50% female), 29.1% with overt diabetic macrovascular
complications (mostly cardiovascular complications with
no significant difference in sex distribution and were all
documented), 3.8% with microalbuminuria and 3.8% with
diabetic retinopathy (documented). In addition, 48.7%
were on insulin therapy and 23% were active smokers.
Clinical and demographic characteristics of the type 2 dia-
betic participants and the levels of plasma Ang-2 and
sTie-2 are shown in (Table 1). Levels of Ang-2 were signif-
icantly positively associated with BMI, whereas levels of
sTie-2 were negatively associated with age of participants.
Levels of Ang-2 and sTie-2 did not differ significantly
between sexes and were independent of smoking status of
the participants. No statistically significant associations
were observed between levels of Ang-2 or sTie-2 and the
waist to height ratio of participants or duration since diag-
nosis of diabetes.
2. Ang-2 relationships in type 2 diabetic subjects
After controlling for age and BMI, levels of plasma Ang-2
were positively associated with levels of sTie-2 (r = 0.355,
p = 0.002), plasma levels of insulin, creatinine, GGT
(Figure 1A) and HOMA-IR, whereas they were negatively
associated with diastolic blood pressure (Figure 1B) and
GFR (p = 0.001) (Figure 1C, Table 2). In addition, Ang-2
levels were significantly higher among subjects with insu-
lin therapy, diabetic polyneuropathy, and diabetic macro-
angiopathy (Table 1). Importantly, multivariate analysis
tests controlled for diabetic therapy, diabetic polyneuropa-
thy, serum creatinine, and levels of GGT, showed that
Ang-2 remained significantly higher among diabetic sub-
jects with macrovascular disease when compared to those
without macrovascular complications. However, levels of
Ang-2 did not remain significantly different between parti-
cipants with or without diabetic polyneuropathy after con-
trolling for the presence of macrovascular complications.
Interestingly, linear multiple regression analysis showed
that plasma GGT levels are the only predictor for circulat-
ing plasma Ang-2 in type 2 diabetes mellitus (Table 3).
Furthermore, no statistically significant associations were
observed between plasma levels of Ang-2 and the waist to
height ratio, duration since diagnosis of diabetes, and
Table 1 Clinical and demographic characteristics of type 2 diabetic participants and their relationships with levels of
Ang-2 and Tie-2 after controlling for age and BMI
Parameters Participants (n = 80) p- value
Sex (%) 47.7 (female) NS
Age (years) 65 ± 7
‡(r = -0.349, p < 0.002)
BMI (kg/m
2)3 2 ± 6
†(r = 0.277, p < 0.01)
Waist to height ratio 0.66 ± 0.12 NS
Duration of diabetes (years) 15 ± 9 NS
*Ang-2 (pg/ml) 2955 (1349-9000)
‡(r = 0.355, p < 0.002)
sTie-2 (ng/ml) 28.34 ± 7.58
†(r = 0.355, p < 0.002)
Active smokers (%) 23 NS
Therapy
†(p < 0.04)
Insulin therapy (%) 48.7
Oral anti-diabetic therapy (%) 51.3
Systolic blood pressure (mmHg) 145 ± 21 NS
Diastolic blood pressure (mmHg) 82 ± 14
†(r = -0.259, p < 0.02)
Diabetic retinopathy (%) 3.8 NS
Microalbuminuria (%) 3.8 NS
Polyneuropathy (%) 50
†(p < 0.01)
#Macro-vascular complications (%) 29.1
†(p < 0.009)
Data are expressed as mean ± standard deviation or as percentage. (*): data not normally distributed, expressed as a median and range, and log10- transformed
for analysis. (
#): included cardiac, cerebral or peripheral vascular disease. (
†): significantly associated with levels of Ang-2. (
‡): significantly associated with levels of
sTie-2. NS: not significant.
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observed between Ang-2 levels and the levels of testoster-
one in male (mean 3.45 ± 1.5 ng/ml) as well as in female
(mean 0.16 ± 0.13 ng/ml) participants. In addition, no
significant associations were observed between levels of
Ang-2 and the levels of estradiol in female [median 9,
range (9-128) pg/ml] and in male [median 24, range
(13-70) pg/ml] participants. As expected, because of few
reported cases, no significant differences were observed in
the levels of circulating Ang-2 in subjects with diabetic
retinopathy, or microalbuminuria.
3. sTie-2 relationships in type 2 diabetic subjects
Studying the relationships of sTie-2 after controlling for
age and BMI showed that levels of circulating sTie-2 posi-
tively associated with HbA1c (Figure 2A), fasting plasma
glucose (Figure 2B), insulin (Figure 2C), HOMA-IR, serum
triglyceride levels and liver function parameters (AST,
ALT and GGT, all p < 0.05) (Table 2). Further controlling
for levels of serum triglyceride and liver function para-
meters showed that sTie-2 levels still remained signifi-
cantly associated with HbA1c (r = 0.453, p < 0.000).
Moreover, linear multiple regression analysis (Table 4),
indicated that HbA1c, insulin levels and HOMA-IR inde-
pendently associated with sTie-2 levels in type 2 diabetic
subjects. No significant associations were observed
between levels of sTie-2 and anthropometric data and
with parameters of renal function, blood pressure, pre-
sence of micro-and macrovascular complications, and type
of diabetic therapy. In addition, there were no significant
associations between levels of sTie-2 and the plasma levels
of testosterone in male as well as plasma levels of estradiol
in female participants.
Discussion
This is the first study simultaneously investigating circu-
lating levels of Ang-2 and sTie-2 in subjects with estab-
lished type 2 diabetes mellitus. We found that: (1) Levels
 
 
 
 
 
 
 
 
  
 
 
A B
C 
Figure 1 Associations of Ang-2 with the levels of GGT (A), diastolic blood pressure (B), and GFR (C), in type 2 diabetic subjects.
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overt macrovascular complications. (2) Levels of serum
GGT predict levels of circulating Ang-2. (3) Levels of
sTie-2 are independently associated with HbA1c,p l a s m a
insulin levels and HOMA-IR. (4) There are no significant
associations between levels of sTie-2 and the presence of
micro-and macrovascular complications including
diabetic polyneuropathy. (5) There are no gender differ-
ences in levels of Ang-2 and sTie-2 in diabetic subjects.
Potential effects of Ang-2 in diabetic patients
It is well established that Ang-2 modulates endothelial cell
biology and destabilizes blood vessels to facilitate angio-
genesis. Ang-2 is a key angiogenic hypoxia-induced
growth factor [23]. Increasing evidence suggests that
targeting the Ang-2/Tie-2 signaling pathway to inhibit the
function of Tie-2 expressing macrophages might extend
the effect of vascular-targeting therapies in cancer patients
[24]. Also, restoration of Ang-2 to Ang-1 ration may be a
novel therapeutic strategy for the treatment of diabetic
myocardial ischemic disease [25]. Moreover, in diabetes
mellitus, chronic hyperglycemia causes an accelerated for-
mation of advanced glycation end products (AGE) and
mitochondrial overproduction of reactive oxygen species
(ROS). The resulting toxic and oxidative stress in vascular
endothelium promotes micro-and macrovascular compli-
cations [26,27]. Amongst multiple pathological changes in
gene expression, AGE and ROS lead to the up-regulation
of Ang-2 mRNA expression [28], which promotes vascular
permeability, destabilization and sprouting [29]. In this
study, subjects with diabetic macrovascular complications,
in particular those with cardiovascular disease had higher
serum levels of Ang-2 than subjects without macrovascu-
lar complications. This is supported by a previous in vitro
Table 2 Laboratory parameters of type 2 diabetic participants and their relationships with levels of Ang-2 and sTie-2
after controlling for age and BMI
Parameters Participants (n = 80) p- value
*HbA1c (%) 7.6 (6-12.9)
‡(r = 0.526, p < 0.000)
Fasting blood Glucose (mg/dl) 152 ± 55
‡(r = 0.353, p < 0.005)
C-Peptide (ng/ml) 2.5 ± 1.3 NS
*Insulin (μU/ml) 11 (1-99.7)
†(r = 0.355, p < 0.004),
‡(r = 0.289, p < 0.02)
*HOMA-IR 4 (0-57.7)
†(r = 0.334, p < 0.007),
‡ (r = 0.322, p < 0.01)
Total cholesterol (mg/dl) 187 ± 47 NS
LDL-cholesterol (mg/dl) 102 ± 40 NS
*HDL-cholesterol (mg/dl) 44 (26-117) NS
Triglyceride (mg/dl) 198 ± 109
‡(r = 0.305, p < 0.01)
Creatinine (mg/dl) 1.09 ± 0.27
†(r = 0.345, p < 0.003)
GFR (ml/min/1.73 m
2)6 6 ± 1 5
†(r = -0.374, p < 0.001)
*CRP (mg/dl) 0.27 (0.01-3.2) NS
Bilirubin (mg/dl) 0.62 ± 0.22 NS
*AST (U/l) 24 (12-53)
‡(r = 0.452, p < 0.000)
ALT(U/l) 27 ± 11
‡(r = 0.369, p < 0.002)
*GGT(U/l) 32 (8-165)
†(r = 0.454, p < 0.000),
‡(r = 0.483, p < 0.000)
*SHBG (nmol/l) 33 (12.8-189) NS
Data are expressed as mean ± standard deviation. (*): data not normally distributed, expressed as a median and range, and log10- transformed for analysis.
HOMA-IR: homeostasis model assessment for insulin resistance, LDL: low density lipoprotein, HDL: high density lipoprotein, GFR: glomerular filtration rate, CRP: C-
reactive protein, AST: aspartate aminotransferase. ALT: alanin aminotransferase, GGT: gamma-glutamyl transferase, SHBG: sex hormone binding globulin. (
†):
significantly associated with levels of Ang-2. (
‡): significantly associated with levels of sTie-2. NS: not significant.
Table 3 Multiple regression analysis with levels of plasma
Ang-2 as dependent factor in studied type 2 diabetic
subjects
Parameters Standard error p-value
BMI 0.004 0.11
Therapy 0.056 0.89
Diastolic blood pressure 0.002 0.09
Polyneuropathy 0.050 0.09
Macrovascular complications 0.058 0.87
*Insulin 0.180 0.56
*HOMA-IR 0.162 0.66
Creatinine 0.140 0.80
GFR 0.002 0.08
*GGT 0.080 0.04
Significant p-values are highlighted in bold
(*): data not normally distributed and log10- transformed for analysis. BMI:
body mass index, HOMA-IR: homeostasis model assessment for insulin
resistance, GFR: glomerular filtration rate, GGT: gamma-glutamyl transferase.
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Ang-2 leading to increased myocardial apoptosis,
increased infarction size and impaired myocardial angio-
genesis [25]. Furthermore, in this study, we found that
levels of serum GGT independently predict levels of circu-
lating Ang-2 in type 2 diabetic subjects. GGT has been
shown to be directly involved in the generation of ROS
[30]. Serum levels of GGT were previously reported as
markers of oxidative stress [31,32] and have been shown
to be associated with hypertension, cardiovascular disease
and peripheral vascular disease [33,34]. Therefore, our
finding of high levels of serum GGT as an independent
predictor for Ang-2 levels in type 2 diabetes mellitus could
explain the association of type 2 diabetes and Ang-2 and
further supports the hypothesis that therapeutic strategies
for reduction of oxidative stress in diabetes mellitus might
lower the incidence of micro-and macro-vascular compli-
cations [35,36]. In addition, recent data showed that
pharmaco-therapeutic interventions using pioglitazone
can modulate vascular remodeling biomarkers such as
A   B
C 
Figure 2 Associations of sTie-2 with HbA1c (A), fasting plasma glucose (B), and plasma insulin (C), in type 2 diabetic subjects.
Table 4 Multiple regression analysis with levels of
circulating sTie-2 as dependent factor in type 2 diabetic
participants
Parameters Standard error p-values
Age 0.111 0.12
*HbA1c 15.174 0.01
Fasting blood glucose 0.078 0.06
*Insulin 24.553 0.03
*HOMA-IR 24.696 0.03
Triglyceride 0.007 0.10
*AST 8.244 0.61
ALT 0.089 0.07
*GGT 2.627 0.06
Significant p-values are highlighted in bold
(*): data not normally distributed and log10- transformed for analysis. HOMA-
IR: homeostasis model assessment for insulin resistance, AST: aspartate
aminotransferase, ALT: alanin aminotransferase, GGT: gamma-glutamyl
transferase.
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peroxisome proliferator-activated receptor gamma stimu-
lation [37].
Potential effects of sTie-2 in diabetic patients
On the other hand, Tie-2 appears to be important for
angiogenic remodeling and vascular stabilization and
has a functional role in pathological angiogenesis in
a d u l tt i s s u e[ 3 8 ] .H o w e v e r ,t h ee x a c tr o l eo ft h es o l u b l e
form of his receptor in plasma is still not understood.
sTie-2 has been shown to inhibit angiogenesis by limit-
ing circulating Ang-1 and Ang-2 from presentation to
tissue endothelial Tie-2, with subsequent loss of vessel
stabilization signaling [39]. Elevated plasma levels of
sTie-2 have been observed in states of inflammation,
malignancies [40], type 2 diabetes and coronary heart
disease [41]. In this study, there were no direct associa-
tions between serum levels of sTie-2 and the presence
of diabetic micro-and macrovascular complications, but
we found that levels of HbA1c,i n s u l i n ,a n dH O M A - I R
are independent predictors for sTie-2 levels in type 2
diabetic subjects. Hyperinsulinemia and insulin resis-
tance contribute to vascular injury and the atherosclero-
tic process [42] and it is well established that in patients
with type 2 diabetes the risk of diabetic vascular compli-
cations is strongly associated with the degree of glycae-
mic control [43]. Indeed, the potential association of the
levels of sTie-2 and HbA1c that has been observed in
this study is consistent with the results of previous in
vivo observations [25]. Hyperglycemia disturbs the
Angiopoietin/Tie-2 system toward lowering the tissue
Tie-2 expression and increasing circulating plasma sTie-
2 hence might contribute to an impaired angiogenesis.
Moreover, recent studies on non-diabetic subjects
showed higher plasma levels of Ang-2 in women than in
men and that levels Ang-2 and sTie-2 are modulated by
estrogen [17,44]. Our data show no significant differ-
ences in levels of Ang-2 and sTie-2 between men and
women with diabetes, which might be due to the fact
that the study included only elderly diabetic men and
post-menopausal women (age 65 ± 7 years). Further stu-
dies in pre-menopausal women are required to address
this issue.
Limitations of the study
It has to be stressed that this present study is limited by
its cross-sectional design. Although the mechanisms
mentioned can describe the associations of Ang-2 as
well as sTie-2 with type 2 diabetes mellitus, the causal
relationship is still unclear. Longitudinal studies on type
2 diabetic subjects could provide a better basis to eluci-
date the exact impact of sTie-2 in the pathogenesis of
diabetes and its complications.
Conclusion
Our data show that levels of serum GGT, which may
serve as a maker for oxidative stress, could predict Ang-2
levels, which further relate to macrovascular disease,
while HbA1c, insulin levels and HOMA-IR might predict
levels of circulating plasma sTie-2 in type 2 diabetic sub-
jects. In addition, the study demonstrates that there is no
gender specific difference in the levels of Ang-2 and
sTie-2 in elderly type 2 diabetic subjects with comparable
distributions of diabetic complications. Therefore, circu-
lating Ang-2 could serve as a new marker of oxidative
stress and vasculopathy while sTie-2 seems to primarily
reflect long-term metabolic control in advanced type 2
diabetes.
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